SHEL vs. GSK
SHEL (Shell plc) and GSK (GlaxoSmithKline plc) are both stocks. SHEL operates in Oil & Gas Integrated (Energy), while GSK operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, SHEL returned 9.11%/yr vs 4.69%/yr for GSK. At a 0.35 correlation, their price movements are largely independent.
Performance
SHEL vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SHEL achieves a 10.42% return, which is significantly higher than GSK's 5.12% return. Over the past 10 years, SHEL has outperformed GSK with an annualized return of 9.11%, while GSK has yielded a comparatively lower 4.69% annualized return.
SHEL
- 1D
- 1.08%
- 1M
- -7.06%
- YTD
- 10.42%
- 6M
- 11.78%
- 1Y
- 14.26%
- 3Y*
- 14.65%
- 5Y*
- 19.76%
- 10Y*
- 9.11%
GSK
- 1D
- 0.14%
- 1M
- -1.25%
- YTD
- 5.12%
- 6M
- 6.09%
- 1Y
- 38.10%
- 3Y*
- 16.17%
- 5Y*
- 4.56%
- 10Y*
- 4.69%
SHEL vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SHEL Shell plc | 10.42% | 22.16% | -0.87% | 20.19% | 36.18% | 34.27% | -41.08% | 6.38% | -7.23% | 21.67% |
GSK GlaxoSmithKline plc | 5.12% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Correlation
The correlation between SHEL and GSK is -0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.00 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.08 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Jul 21, 2005 | 0.35 |
The correlation between SHEL and GSK shifts across timeframes, from -0.00 (1 year) to 0.35 (all time), reflecting how their relationship changes across market environments.
Fundamentals
SHEL:
$227.18B
GSK:
$103.36B
SHEL:
$6.39
GSK:
£2.85
SHEL:
12.46
GSK:
13.47
SHEL:
0.62
GSK:
0.90
SHEL:
0.87
GSK:
2.40
SHEL:
1.31
GSK:
3.32
SHEL:
$266.82B
GSK:
£32.78B
SHEL:
$41.65B
GSK:
£23.87B
SHEL:
$57.44B
GSK:
£11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SHEL vs. GSK — Risk / Return Rank
SHEL
GSK
SHEL vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Shell plc (SHEL) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SHEL | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.77 | ||
| Sortino ratioReturn per unit of downside risk | -1.06 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.26 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 0.92 | 2.05 | -1.13 |
| Martin ratioReturn relative to average drawdown | 3.26 | 5.17 | -1.91 |
Loading charts...
Drawdowns
SHEL vs. GSK - Drawdown Comparison
The maximum SHEL drawdown since its inception was -71.57%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for SHEL and GSK.
Loading charts...
Drawdown Indicators
| SHEL | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -71.57% | -55.70% | -15.87% |
Max Drawdown (1Y)Largest decline over 1 year | -15.53% | -18.63% | +3.10% |
Max Drawdown (3Y)Largest decline over 3 years | -18.47% | -28.46% | +9.99% |
Max Drawdown (5Y)Largest decline over 5 years | -25.04% | -50.10% | +25.06% |
Max Drawdown (10Y)Largest decline over 10 years | -71.57% | -50.10% | -21.47% |
Current DrawdownCurrent decline from peak | -14.62% | -15.74% | +1.12% |
Average DrawdownAverage peak-to-trough decline | -16.73% | -18.87% | +2.14% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.41% | 7.40% | -2.99% |
Volatility
SHEL vs. GSK - Volatility Comparison
The current volatility for Shell plc (SHEL) is 6.17%, while GlaxoSmithKline plc (GSK) has a volatility of 7.15%. This indicates that SHEL experiences smaller price fluctuations and is considered to be less risky than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SHEL | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.17% | 7.15% | -0.98% |
Volatility (6M)Calculated over the trailing 6-month period | 17.89% | 18.73% | -0.84% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.43% | 26.67% | -5.24% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.09% | 25.11% | -0.02% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 30.80% | 22.89% | +7.91% |
Dividends
SHEL vs. GSK - Dividend Comparison
SHEL's dividend yield for the trailing twelve months is around 3.71%, more than GSK's 3.41% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.41% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
SHEL Shell plc | 3.71% | 3.90% | 4.39% | 3.76% | 3.48% | 3.78% | 5.69% | 6.27% | 6.27% | 2.75% | 6.49% | 8.17% |
Financials
SHEL vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Shell plc and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SHEL vs. GSK - Profitability Comparison
SHEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Shell plc reported a gross profit of 13.31B and revenue of 69.57B. Therefore, the gross margin over that period was 19.1%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
SHEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Shell plc reported an operating income of 10.35B and revenue of 69.57B, resulting in an operating margin of 14.9%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
SHEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Shell plc reported a net income of 5.68B and revenue of 69.57B, resulting in a net margin of 8.2%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
SHEL and GSK have a correlation of -0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GSK has higher volatility (7.15%) compared to SHEL (6.17%). In terms of maximum drawdown, SHEL dropped -71.57% vs GSK's -55.70%.
GSK currently has the higher Sharpe Ratio (1.44 vs 0.67), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SHEL and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer